Biological drugs targeting the immune response in the therapy of psoriasis

Original Research

(3133) Views  (1115) Full article downloads

Authors: Saveria Pastore, Emanuela Gubinelli, Luca Leoni, Desanka Raskovic, Liudmila Korkina

Published Date August 2008 Volume 2008:2(4) Pages 687 - 697

DOI: http://dx.doi.org/10.2147/BTT.S2763

Saveria Pastore¹, Emanuela Gubinelli², Luca Leoni², Desanka Raskovic², Liudmila Korkina¹

¹Laboratory of Tissue Engineering and Cutaneous Physiopathology; ²Second Dermatology Unit, Istituto Dermopatico dell’Immacolata, IRCCS, Roma, Italy

Abstract: Chronic plaque psoriasis affects more than 2% of world population, has a chronic recurrent behavior, gives a heavy burden to the patients’ quality of life, and hence remains a huge medical and social problem. The clinical results of conventional therapies of psoriasis are not satisfactory. According to the current knowledge of the molecular and cellular basis of psoriasis, it is defined as an immune-mediated chronic inflammatory and hyperproliferative skin disease. A new generation of biological drugs, targeting molecules and cells involved into perturbed pro-inflammatory immune response in the psoriatic skin and joints, has been recently designed and applied clinically. These biological agents are bioengineered proteins such as chimeric and humanized antibodies and fusion proteins. In particular, they comprise the antitumor necrosis factor-α agents etanercept, infliximab, and adalimumab, with clinical efficacy in both moderate-severe psoriasis and psoriatic arthritis, and the anti-CD11a efalizumab with selective therapeutic action exclusively in the skin. Here, we overview recent findings on the molecular pathways relevant to the inflammatory response in psoriasis and present our clinical experience with the drugs currently employed in the dermatologic manifestations, namely etanercept, infliximab, and efalizumab. The growing body of clinical data on the efficacy and safety of antipsoriasis biological drugs is reviewed as well. Particular focus is given to long-term safety concerns and feasibility of combined therapeutic protocols to ameliorate clinical results.

Keywords: psoriasis, immune-mediated inflammation, etanercept, infliximab, efalizumab